DRUG THERAPY OF HYPOPIGMENTARY DISORDERS OF THE SKIN: A HOSPITAL-BASED STUDY
DOI:
https://doi.org/10.22159/ijpps.2023v15i4.47383Keywords:
Quality of life, Topical Therapy, PhototherapyAbstract
Objective: To determine the pattern of drug use, adverse events (AEs), and quality of life (QOL) in hypopigmentary disorders of the skin.
Methods: A prospective, observational study was conducted on 48 newly diagnosed and untreated participants with hypopigmentary disorders, who attended the dermatology outpatient department (OPD) of a tertiary care hospital, in Bangalore, India. The pattern of drug therapy and AEs to the therapy were analyzed using descriptive statistics. The dermatology life quality index (DLQI) score for QOL was assessed before and after treatment using analysis of variance (ANOVA). The participants were monitored every 30 days for three months to study the appropriateness, and changes in prescription patterns, AEs, and QOL.
Results: Male participants had a mean age of 36.69 ± 15.58, while female participants had a mean age of 40.96 ± 11.88. The different classes of drugs used were calcineurin inhibitors, growth factors, melanizing agents, glucocorticoids (GCs), antifungals, and anti-lepra drugs. QOL improved after treatment. The most common AEs include gastritis (16.6%) and acneiform eruption (10.41%).
Conclusion: This study has helped in determining the different patterns of drugs used in hypopigmentary disorders and their positive impact on QOL. The individualized prescribing pattern could improve the clinical and psychosocial outcome of the disease in the future.
Downloads
References
Patel AB, Kubba R, Kubba A. Clinicopathological correlation of acquired hypopigmentary disorders. Indian J Dermatol Venereol Leprol. 2013 May-Jun;79(3):376-82. doi: 10.4103/0378-6323.110800. PMID: 23619442.
Fitzpatrick TB, Ortonne JP. Disorders of Melanocytes: Normal skin color and General considerations of pigmentary disorders. In:Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick’s Dermatology, in General, medicine.6th ed. Vol 1. New York: McGraw-Hill companies; 2003.p. 819-879
Hill JP, Batchelor JM. An approach to hypopigmentation. BMJ. 2017 Jan 12;356: i6534. doi: 10.1136/bmj. i6534. PMID: 28082370.
Dogra S, Sarangal R. Pigmentary disorders: An insight. Pigment Int [serial online] 2014 [cited 2023 Feb 5]; 1:5-7. Available from: https://www.pigmentinternational.com/text.asp?2014/1/1/5/135429
Anstey AV. Disorders of skin color. In: Breathnach SM, Cox NH, Griffiths CEM, editors. Rook’s Textbook of Dermatology. 8th ed vol 3. Oxford: Wiley- Blackwell Publishing Ltd; 2010. p.58.1 – 58.59
Kumarasinghe P, Uprety S, Sarkar R. Hypopigmentary disorders in Asian patients. Pigment Int [serial online] 2017 [cited 2023 Feb 5]; 4: 13-20. Available from: https://www.pigmentinternational.com/text.asp?2017/4/1/13/208351
Narayanaswamy R, Ismail IS. Role of Herbal Medicines in Vitiligo Treatment - Current Status and Future Perspectives. Asian J Pharm Clin Res. 2018,11(9):19-23
Belgaumkar V A, Chavan R B, Deshmukh N S, Warke N V. Impact of Vitiligo on Quality of Life: A Cross-sectional Pilot Study from Western India. J Skin Stem Cell. 2020;7(2): e107184. doi: 10.5812/jssc.107184.
Finlay AY. Quality of life indices. Indian J Dermatol Venereol Leprol. 2004 May-Jun;70(3):143-8. PMID: 17642592.
Mishra N, Rastogi MK, Gahalaut P, Agrawal S. Dermatology Specific Quality of Life in Vitiligo Patients and Its Relation with Various Variables: A Hospital Based Cross-sectional Study. J Clin Diagn Res. 2014 Jun;8(6): YC01-3. doi: 10.7860/JCDR/2014/8248.4508. PMID: 25121050
Reghu R, James E. Epidemiological profile and treatment pattern of vitiligo in a tertiary care hospital. Int J Pharm Pharm Sci .2011;3(2):137141
Singam A, Chokhandre M, Parul G. Prescription Pattern in Management of Vitiligo in A Tertiary Care Centre: A Prospective Observational Study. Indo-American Journal of Pharmaceutical Research.2020:10(02);649-655
Indraneel M, Govardhan M, Kiranmayi T, Sneha reddy PR, Surekha A, Divya Rekha O, et al. Clinical profile, prescription patterns, and adverse drug reactions in patients with vitiligo: a prospective study. Asian J Pharm Clin Res. 2021;14(4):51-55
Gupta AK, Foley KA. Antifungal Treatment for Pityriasis Versicolor. J Fungi (Basel). 2015 Mar 12;1(1):13-29. doi: 10.3390/jof1010013. PMID: 29376896.
Dina Y, McKesey J, Pandya AG. Disorders of Hypopigmentation. J Drugs Dermatol. 2019 Mar 1;18(3): s115-s116. PMID: 30909355.
Madireddy S, Crane JS. Hypopigmented Macules. In: StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL) 2022[cited in 2023 Jan 19]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563245/
Jha AK, Karki S. Pigmentary Disorders; Vitiligo and Melasma in Context of South Asian Countries: A Psychosocio-Cosmetic Challenge. Int J DermatolClin Res 2015; 1(2): 024-030. doi: 10.17352/2455-8605.000010.
Malathi M, Thappa DM. Fixed-duration therapy in leprosy: limitations and opportunities. Indian J Dermatol. 2013 Mar;58(2):93-100. doi: 10.4103/0019-5154.108029. PMID: 23716796.
Vachiramon V, Thadanipon K. Postinflammatory hypopigmentation. Clin Exp Dermatol. 2011 Oct;36(7):708-14. doi: 10.1111/j.1365-2230.2011.04088. x. PMID: 21671990.
Naga Navya CH, Jain GK, Jain V. Existing and Novel therapies for Psoriasis. Asian J Pharm Clin .2018. 11(12): 82-87
Al-shahwan, M, Gacem S. A, Shamseddin S, Sammour, M. Vitamin D Impact on Human Health and its Relation with Several Diseases. International Journal of Applied Pharmaceutics.2018:10(6):60–64. doi: 10.22159/ijap.2018v10i6.28776
Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, Kim GM. Phototherapy for Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol. 2017 Jul 1;153(7):666-674. doi: 10.1001/jamadermatol.2017.0002. PMID: 28355423.
Echekwube PO, Olasode OA, Onayemi EO. PUVAsol therapy in the management of vitiligo: outcome in a dermatology clinic in SouthWest Nigeria. Int J Res Dermatol 2019; 5:247-53
Subhashini PK, Sankar K, Kambar C, VenkataRamana V. Comparative Study Of Efficacy and Safety of Topical Active Fragment of Basic Fibroblast Growth Factor (B FGF) 0.1% Solution V/S Betamethasone Valerate 0.1% Ointment in the Treatment of Vitiligo Patients. IOSR Journal of Dental and Medical Sciences 2015;14(6);41-47
Pandhi D, Chhabra N. New insights in the pathogenesis of type 1 and type 2 lepra reaction. Indian J Dermatol Venereol Leprol. 2013 Nov-Dec;79(6):739-49. doi: 10.4103/0378-6323.120719. PMID: 24177605.
Arco RD, Nardi SM, Bassi TG, Paschoal Vdel A. Diagnosis and medical treatment of neuropathic pain in leprosy. Rev Lat Am Enfermagem. 2016 Aug 8; 24: e2731. doi: 10.1590/1518-8345.0676.2731. PMID: 27508904.
Attallah DA, A. Abdullah MA, E. Abou-Taleb DA. Effect of treatment on quality of life in Egyptian vitiligo patients using the Arabic version of Dermatology Life Quality Index. J Curr Med Res Pract [serial online] 2022 [cited 2023 Feb 5]; 7:163-6. Available from: http://www.jcmrp.eg.net/text.asp?2022/7/2/163/346826
Published
How to Cite
Issue
Section
Copyright (c) 2023 GIRISH K., NEEPU GOWDA, JYOTHI R., VIJAYAMATHY ARUNNAIR
This work is licensed under a Creative Commons Attribution 4.0 International License.
